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Abstract
Background: Biomarkers of placental function can potentially aid the diagnosis and prediction of pregnancy
complications. This randomised controlled pilot trial assessed whether for women with reduced fetal movement
(RFM), intervention directed by the measurement of a placental biomarker in addition to standard care was feasible
and improved pregnancy outcome compared with standard care alone.
Methods: Women aged 16–50 years presenting at eight UK maternity units with RFM between 36+0 and 41+0 weeks’
gestation with a viable singleton pregnancy and no indication for immediate delivery were eligible. Participants were
randomised 1:1 in an unblinded manner to standard care and a biomarker blood test result revealed and acted on
(intervention arm) or standard care where the biomarker result was not available (control arm). The objectives were to
determine the feasibility of a main trial by recruiting 175–225 participants over 9months and to provide proof of concept
that informing care by measurement of placental biomarkers may improve outcome. Feasibility was assessed via the
number of potentially eligible women, number recruited, reasons for non-recruitment and compliance. Proof of concept
outcomes included the rates of the induction of labour and caesarean birth, and a composite adverse pregnancy outcome.
Results: Overall, 2917 women presented with RFM≥ 36 weeks, 352 were approached to participate and 216 (61%)
were randomised (intervention n = 109, control n = 107). The main reason for not approaching women was resource/
staff issues (n = 1510). Ninety-seven women declined the trial, mainly due to not liking blood tests (n = 24) or not
wanting to be in a trial (n = 21). Compliance with the trial interventions was 100% in both arms. Labour was induced in
97 (45%) participants (intervention n = 49, control n = 48), while 17 (9%) had planned caesarean sections (intervention
n = 9, control n = 8). Overall, 9 (8%) babies in the intervention arm had the composite adverse pregnancy outcome
versus 4 (4%) in the control arm.
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Conclusions: A main trial using a placental biomarker in combination with delivery, as indicated by the biomarker, in
women with RFM is feasible. The frequency of adverse outcomes in this population is low, hence, a large sample size
would be required along with consideration of the most appropriate outcome measures.
Trial registration: ISRCTN, ISRCTN12067514; registered 8 September 2017.
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Introduction
In 2015, the stillbirth rate in the UK ranked 24th out of 49
high-income countries [1] and while the rate has declined
over recent years [2], further reduction is a national prior-
ity [3]. Maternal perception of reduced fetal movements
(RFM) is associated with stillbirth [3–7] and is thought to
be a symptom of placental dysfunction restricting the sup-
ply of nutrients or oxygen to the fetus [8, 9]. A systematic
review of management for RFM concluded that there was
insufficient evidence to guide practice and that high-
quality trials were required [10]. Furthermore, the need
for evidence is supported by the two UK Confidential En-
quiries into perinatal death which have identified manage-
ment of RFM as a key area for action [11, 12].
The Stillbirth Priority Setting Partnership [13] identified
two priorities relevant to RFM and placental dysfunction:
(i) “which investigations identify a fetus at risk of stillbirth
after a mother has experienced RFM” and (ii) “how can the
structure and function of the placenta be assessed during
pregnancy to detect potential problems and reduce the risk
of stillbirth?” Research into this area also needs to balance
the possibility of increasing perinatal morbidity and mor-
tality by intervening to deliver babies too early versus the
increased risk of stillbirth at later gestational ages [14]. A
systematic review identified three studies including 3475
participants to assess the effectiveness of measuring
placental biomarkers to improve pregnancy outcome and
concluded there was insufficient evidence to draw any con-
clusions [15]. Therefore, studies to evaluate the potential
benefit of assessing placental dysfunction via a novel
biomarker in combination with delivery, as indicated by
the biomarker, in women with RFM at or after 36 weeks’
gestation are warranted.
The multicentre randomised controlled Reduced Fetal
Movement Intervention-2 (ReMIT-2) pilot trial reported
here was based on the design of a single-centre rando-
mised controlled feasibility trial (ReMIT) which investi-
gated the intensive management of RFM via ultrasound
scan and measurement of human placental lactogen (hPL)
as a biomarker of placental dysfunction versus standard
care [16]. The results showed that this type of trial was
feasible with good compliance to the trial intervention
(100% in both arms) and a potential improvement in proof
of concept outcomes [16]. However, during the design
stage of ReMIT-2, we evaluated whether prospective sites
throughout the UK could test for hPL and determined this
would not be viable in a multicentre trial due to the
resource-intensive nature of the assay and the need for
results to be available within 24 h.
A recent systematic review of diagnostic test accuracy
studies evaluated the ability of placental biomarkers to
detect pregnancies ending in the birth of a small for
gestational age (SGA) infant or a stillbirth compared
with those identified via the ultrasound assessment of
estimated fetal weight (EFW). This review determined
that placental growth factor (PlGF) gave the highest
diagnostic odds ratio (49.2; 95% confidence interval [CI]
12.7 to 191) for detecting pregnancies ending in stillbirth
and performed well in the prediction of SGA neonates [17].
As the data were based on 5894 pregnancies of which only
16 ended in stillbirth and no studies investigated EFW in
the prediction of stillbirth, the review concluded that fur-
ther research was required to determine the diagnostic ac-
curacy of placental biomarkers alone and in combination
with EFW in the identification of adverse pregnancy out-
comes [17]. In addition, a cohort study of 300 women with
RFM after 28 weeks’ gestation found that the addition of
PlGF measurement improved the sensitivity for the detec-
tion of a composite adverse pregnancy outcome to 36%
from 19% [18]. Furthermore, automated PlGF assays are
available which are quick and easy to perform, making this
a more viable option for a multicentre trial and clinical
practice. Thus, PlGF was selected as the biomarker for
further evaluation using a composite adverse pregnancy
outcome in ReMIT-2.
PlGF is bound in maternal blood by soluble fms-like
tyrosine kinase-1 (sFlt-1) [19], thus, assays to quantify PlGF
often measure the sFlt-1/PlGF ratio. Currently, the sFlt-1/
PlGF ratio of 38 is advocated by the National Institute for
Health and Care Excellence as an aid in diagnosing pre-
eclampsia in conjunction with other clinical information
[20–22]. A diagnostic test accuracy study conducted in 289
women with RFM and an appropriately grown fetus
showed that a sFlt-1/PlGF ratio of ≥ 38 had a sensitivity of
0.20 (95% CI 0.07 to 0.41) and a specificity of 0.88 (95% CI
0.83 to 0.92) to identify a composite adverse pregnancy
outcome (perinatal death, birthweight < 5th centile, umbil-
ical cord pH < 7.1 or admission to neonatal intensive care
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unit (NICU) for > 48 h) [23]. Although modest, this level of
sensitivity was comparable to, or better than, other
methods currently used to assess RFM, e.g. ultrasound fetal
biometry, liquor volume and umbilical artery Doppler [23].
Views on this level of test accuracy were sought from the
patient and public involvement (PPI) group and an inde-
pendent Trial Steering Committee. Both agreed that the
addition of sFlt-1/PlGF testing to currently available re-
gimes, without a significant reduction in specificity, may
aid the clinical management of women at risk of an adverse
pregnancy outcome and was deemed an appropriate test to
investigate further in this pilot trial.
The ReMIT-2 trial described here was conducted as a
pilot study to assess the feasibility of a large main trial
and to provide initial proof of concept that informing
care by measurement of the sFlt-1/PlGF ratio may improve
neonatal outcomes.
Methods
The reporting of this trial follows the Consolidated Stan-
dards of Reporting Trials (CONSORT) statement extension
to randomised pilot and feasibility trials recommendations
(Additional file 1) [24].
Design
This was a multicentre, randomised (1:1) controlled pilot
trial of standard care informed by the results of an add-
itional blood test for the sFlt-1/PlGF ratio versus stand-
ard care in women presenting with RFM at or after 36+0
weeks’ gestation. The trial was conducted at eight UK
maternity units (detailed in Additional file 2) and the
protocol was published prior to study completion [25].
Participants
Women were eligible if they presented with RFM before
the onset of labour between 36+0 and 41+0 weeks’ gestation
(assessment of gestation was based upon the first trimester
dating scan), had a viable singleton pregnancy with no indi-
cation for immediate delivery and provided written
informed consent. Exclusion criteria were maternal age <
16 years or > 50 years, a fetus known to have any congenital
anomalies as per the Fetal Anomalies Screening
Programme (FASP) [26], multiple pregnancy, women for
whom it was their first attendance to any antenatal care,
previous randomisation into the ReMIT-2 trial and concur-
rent participation in the intervention phase of another clin-
ical trial which determined the timing or mode of delivery.
All participants were contacted for follow-up approxi-
mately 6 weeks after birth and asked to complete a Post-
natal Questionnaire which was sent in the post. The
questionnaire consisted of the SF-12™ Health Survey, the
Generalised Anxiety Disorder 2 (GAD-2) scale [27], par-
ticipant views on the trial and health resource use details.
Women who declined to take part were asked if they
were willing to complete an anonymous survey about
their reasons for not participating in the trial. At the
Chief Investigator’s site only, this sub-group was also
asked if they were willing to have a short interview to
further explore their reasons for not participating.
Trial intervention
A blood sample was taken from all participants to measure
the sFlt-1/PlGF ratio using the Elecsys® sFlt-1 and Elecsys®
PlGF immunoassays (Roche Diagnostics; Germany). Par-
ticipants were randomised 1:1 to standard care with either
the blood sample tested locally at the time and the results
revealed and acted on (intervention arm), or for the blood
sample to be tested at a later time by a central laboratory
so the result was not available and could not be acted on
(control arm). Participants in the intervention arm with a
sFlt-1/PlGF ratio ≥ 38 were offered delivery from 37+0
weeks by the most appropriate method with induction of
labour (IOL) ideally commencing within 48 h of the offer.
Those in the intervention arm with a sFlt-1/PlGF ratio <
38 or those in the control arm continued with usual care
[4]. Participants in both arms were free to decline the
recommended management plan and could return for any
further episodes of RFM prior to delivery.
Central analysis of all blood samples, i.e. from both the
intervention and control arms, was conducted using the
same Elecsys® sFlt-1 and Elecsys® PlGF immunoassays
(Roche Diagnostics; Germany) as used locally by each site.
This was to provide a measure of reliability for the sFlt-1/
PlGF ratio test and ensure that the results were consistent
irrespective of where the assays were performed. The
central analysis of sFlt-1 and PlGF was done in batches on
a 6 monthly basis due to potential stability issues. The
samples were also analysed centrally for hPL and other ex-
ploratory biomarkers as potential candidate markers of
placental dysfunction to compare their diagnostic
accuracy versus the sFlt-1/PlGF ratio test (results will be
reported separately).
Outcome measures
The main outcome was to determine the feasibility of a
large-scale trial by aiming to recruit 175–225 participants
over a period of 9months, and associated outcome mea-
sures included number of potentially eligible women,
number of women recruited at each site, proportion lost
to follow-up and reasons for loss to follow-up, spectrum of
clinical characteristics of women at randomisation, reasons
for non-recruitment, compliance with the trial interven-
tions and reasons for non-compliance and completeness
of data collection for planned outcomes in a main trial.
The thresholds for most of these feasibility outcomes were
not specified as it was anticipated that results from this ex-
ternal pilot trial would inform any changes required before
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proceeding to a main trial. Additional information on
feasibility describing participants’ and health professionals’
views and experiences of the trial will be reported
separately.
Proof of concept outcomes for the mother included fre-
quency of IOL or planned caesarean section and reasons
for these procedures, frequency of maternal hypertensive
disorders defined as the development of gestational hyper-
tension or preeclampsia, maternal deaths prior to discharge
or admissions to the intensive care unit (ICU). Proof of
concept outcomes for the baby included stillbirths and
deaths before discharge, 5-min Apgar score of < 7, umbil-
ical artery pH < 7.05 and admission to the neonatal unit for
> 48 h (these four components also formed the composite
adverse pregnancy measure proposed as the primary out-
come for a main trial at the time of designing ReMIT-2);
SGA (< 10th centile on neonatal birthweight standards
[28–30]); use of therapeutic cooling; length of stay in hos-
pital; duration of respiratory support; and number of de-
pendency days on the neonatal unit. For calculating the
Gestation Related Optimal Weight (GROW) birthweight
standard, the woman’s ethnicity was used with an ethnicity
of white being classified as British European. In addition,
the diagnostic performance of the placental factor test in
participants allocated to the control arm only was included
as a proof of concept outcome. The test results for partici-
pants in the intervention arm were not included in this out-
come since the management of those participants could
have been affected by the sFlt-1/PlGF result, potentially
biasing the diagnostic performance outcome.
The impact on quality of life and resource use was
assessed by the SF-12™ Health Survey [31] and a Health
Resource Use Questionnaire and these results, along with
the change in GAD-2 scale [27], will be reported separately.
Sample size
As this was a feasibility trial, a formal sample size calcu-
lation for a between-group comparison was not appro-
priate. The target was to recruit 175–225 participants
over 9 months from approximately 6 sites. This number
would give estimated margins of error (half width of
95% CI) for the proportion recruited of approximately
5% and for the proportion lost to follow-up after dis-
charge of approximately 7.5%.
Randomisation
Eligible participants were randomised 1:1 to either the
intervention or the control arm. Randomisation was
stratified by site and number of weeks gestation when
the participant first presented at hospital (< 40 weeks’
gestation or ≥ 40 weeks’ gestation). The randomisation
schedule was based on a computer-generated pseudo-
random code using random permuted blocks of ran-
domly varying size, created by the Nottingham Clinical
Trials Unit (NCTU) and held on a secure University of
Nottingham server.
Investigators and delegated site staff randomised par-
ticipants using an online randomisation system via a se-
cure website developed and maintained by NCTU. It
was not possible to blind participants or site staff to the
allocated arm since those randomised to the intervention
arm had the sFlt-1/PlGF ratio blood sample tested at the
time and their results revealed to inform the next steps
of their management plan.
Statistical analysis
No formal statistical testing was conducted as the feasibil-
ity aims were to assess recruitment rates, proportion lost
to follow-up and clinical characteristics in the target popu-
lation. Descriptive statistics were used to summarise these
results with the mean, standard deviation (SD) and/or me-
dian, minimum and maximum observations being reported
for continuous variables while frequency counts and per-
centages were used for categorical variables. 95% CIs were
calculated for the proportion of women recruited and the
proportion of women lost to follow-up.
The proposed adverse pregnancy outcome for a main
trial was summarised by allocated arm and the difference
between arms presented as a relative risk and risk differ-
ence with 95% CIs. Of the four components of the adverse
outcome, umbilical artery pH is often not measured in
babies who are otherwise apparently healthy at birth, i.e.
with an Apgar score at 5min ≥ 7, particularly as higher
Apgar scores are associated with less acidic umbilical
artery pH values [32, 33]. Thus, for babies with missing
umbilical artery pH data, a result ≥ 7.05 was assumed. We
planned to report the estimates adjusted for the random-
isation stratification variables, however, the models failed
to converge so unadjusted estimates are given.
A scatter plot was used to compare sFlt-1/PlGF ratio
results obtained from the central lab with those from
each site. Agreement between the central lab and site re-
sults around the cut-off level of 38 was determined using
unweighted kappa. A receiver operator characteristic
(ROC) curve was plotted for the sFlt-1/PlGF ratio and
adverse pregnancy outcome to determine the diagnostic
performance of the biomarker test for participants in the
control arm. All analyses were carried out using Stata®
SE 15.1 (StataCorp LP, College Station, TX, USA).
Results
Recruitment to the trial started in March 2018 and fin-
ished as planned in December 2018; follow-up of partici-
pants was completed in April 2019. A total of 2917
women presented with RFM ≥ 36 weeks’ gestation during
the recruitment period (Fig. 1) and the numbers of poten-
tially eligible women at each site ranged from 143–595
(Additional file 2). Of these, 352 (12%) were approached
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and 216 gave consent and were randomised into the
trial (Fig. 1) which represented 7% of those presenting
with RFM (95% CI 6.5 to 8.4%) and 61% of those
approached (95% CI 56.2 to 66.3%). The number of
women recruited at each site ranged from 12–58 (Add-
itional file 2). A total of 85 (39%; 95% CI 33 to 46%)
participants (40 in the intervention arm, 45 in the
control arm) were lost to follow-up, all of whom did
not return the Postnatal Questionnaire despite two
reminders being sent (Fig. 1).
The main reasons for not approaching potentially
eligible women were resource or staff issues (including
women who presented out of hours; n = 1510) and women
missed by trial staff (including women missed within nor-
mal working hours; n = 573; Fig. 1). Of the 97 women who
were approached and declined to join the trial, the main
reasons given were that they did not like having blood tests
(n = 24) or did not want to be in a research trial (n = 21).
Only 2 women who declined did so because they did not
think the blood test was reliable enough to predict compli-
cations later in their pregnancy. None of the women who
declined wished to discuss their reasons further in a short
interview.
Baseline characteristics
The two allocated arms were similar at the trial entry for
maternal baseline characteristics (Table 1). The mean
age of participants in the trial was 29.8 years, just under
half (47%) were in their first pregnancy and 2 had previ-
ously had a stillbirth. A total of 8 (4%) participants (5 in
Fig. 1 Flow of participants through the trial
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the intervention arm, 3 in the control arm) had a SGA
fetus in their current pregnancy using the
INTERGROWTH-21st birthweight standard [28]. A
similar proportion of participants had previous obstetric
complications (19 in the intervention arm, 23 in the con-
trol arm) with 7 having a SGA baby in a previous preg-
nancy (2 in the intervention arm, 5 in the control arm;
Table 1). All participants had a normal cardiotocograph
(CTG) at trial entry. Of the babies, 113 (52%) were male
(61 in the intervention arm, 52 in the control arm) and
mean gestational age at delivery was 39+5 weeks.
Compliance with allocated trial intervention
In both allocated arms, compliance with the trial inter-
vention, i.e. the process for taking and testing the blood
samples, was 100% (Table 2). All participants in the
intervention arm had a blood sample taken which was
analysed at site to obtain the sFlt-1/PlGF ratio and the
result revealed to the participant. Those in the control
arm all had a blood sample taken, none of which were
analysed at the site and therefore results could not be
revealed to the participant (Table 2).
In the intervention arm, 15/16 participants (94%) with
a sFlt-1/PlGF ratio ≥ 38 were offered expedited delivery
as per the protocol (Table 2). One participant with a
sFlt-1/PlGF ratio ≥ 38 was not offered expedited delivery
due to the clinician recommending to continue the preg-
nancy. Of those in the intervention arm with a sFlt-1/
PlGF ratio < 38, 8/93 (9%) were also offered expedited
delivery although this was not indicated by the blood
test result (Table 2). The reasons for this offer included
the participant wanted IOL (n = 2), clinician decision to
deliver the baby (n = 5) and participant experiencing
recurrent RFM (n = 1). A total of 9 (8%) participants in
the control arm were offered and accepted expedited
delivery as part of standard care.
Completeness of data collection for planned outcomes in
a main trial
The completeness of data collection for the components
of the composite adverse pregnancy outcome proposed
for a main trial was 100% in both allocated trial arms for
stillbirth or death before discharge, 5-min Apgar score
and length of stay in the neonatal unit (Table 3). The
data collection of the umbilical artery pH was lower with
66% completeness in the intervention arm and 58%
completeness in the control arm. However, as all babies
where this data was missing had a 5-min Apgar score ≥
7, an umbilical artery pH ≥ 7.05 was assumed [32, 33],
which gave 100% of participants with an assessable com-
posite adverse pregnancy outcome (Table 3).
For the proposed secondary outcomes for a main trial,
completeness of data collection was 100% for all compo-
nents in both allocated trial arms including birthweight,
use of therapeutic cooling, length of stay in hospital (ba-
bies), duration of mechanical respiratory support, num-
ber of dependency days on the neonatal unit, mode of
delivery, length of stay in the maternity unit (women),
maternal mortality and admission to ICU (women).
Maternal proof of concept outcomes
A total of 20 participants experienced pregnancy compli-
cations after the baseline visit (15 in the intervention
arm, 5 in the control arm; Table 4). Of these, 3 (3%) in
the intervention arm had hypertension compared with 2
(2%) in the control arm. The most common complica-
tion occurring after randomisation was the prelabour
rupture of membranes affecting 9 (8%) in the interven-
tion arm and 1 (1%) in the control arm.
The frequency of IOL was the same in both allocated
trial arms (45%), while the frequency of planned caesarean
section was similar between arms (8% in the intervention
arm, 7% in the control arm; Table 4). The main reason for
IOL in both allocated trial arms was RFM (51% in the
intervention arm, 60% in the control arm), while the main
indication for a planned caesarean section was having had
a previous caesarean section (56% in the intervention arm,
50% in the control arm; Table 4). For those in the inter-
vention arm, delivery offered due to the sFlt-1/PlGF result
was the reason given for 13/49 (27%) participants who
had IOL but only 1/9 (11%) for those who had a planned
caesarean section (Table 4).
There were no maternal admissions to the ICU or mater-
nal deaths prior to discharge and the median length of par-
ticipant stay in the maternity unit was 2 days (interquartile
range 1 to 3).
Neonatal proof of concept outcomes
There were no stillbirths or neonatal deaths before
discharge, 2 babies (1 in the intervention arm, 1 in the
control arm) had a 5-min Apgar score < 7 and a total of 8
babies (4 in each arm) were admitted to the neonatal unit
for > 48 h (Table 5). Four babies (4%) in the intervention
arm had an umbilical artery pH < 7.05 compared with no
babies in the control arm (Table 5). Overall, 9 (8%) babies
in the intervention arm had the composite adverse preg-
nancy outcome compared with 4 (4%) in the control arm
(Table 5); relative risk 2.21 (95% CI 0.70, 6.96); risk differ-
ence 4.51% (95% CI − 1.78%, 10.8%).
Using INTERGROWTH-21st [28] as the birthweight
standard gave a total of 11 (5%) SGA babies (9 in the inter-
vention arm, 2 in the control arm), whereas GROW [30]
gave a total of 22 (10%) SGA babies (15 in the intervention
arm, 7 in the control arm; Table 5). It was not possible to
calculate SGA using the Ponderal Index as planned since
the length of babies is no longer routinely collected at
birth. Of the 22 SGA babies defined by GROW, 16 were
delivered ≤ 39 weeks’ gestation and a greater proportion of
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Table 1 Baseline characteristics
Characteristic Control (n = 107) Intervention (n = 109) Total (n = 216)
Maternal age (years)
Mean (SD) 29.2 (5.7) 30.4 (5.4) 29.8 (5.6)
Gestational age at randomisation (weeks)
Mean (SD) 37.8 (1.2) 37.9 (1.4) 37.9 (1.3)
Stratification variable
≥ 40+0 7 (7%) 10 (9%) 17 (8%)
Ethnicity
White 93 (87%) 93 (85%) 186 (86%)
Black 1 (1%) 5 (5%) 6 (3%)
South Asian 7 (7%) 6 (6%) 13 (6%)
East Asian 3 (3%) 3 (3%) 6 (3%)
Mixed Race 1 (1%) 2 (2%) 3 (1%)
Others 2 (2%) 0 (–) 2 (1%)
BMI at booking visit
Mean (SD) 26.8 (5.6) 27.4 (6.3) 27.1 (6.0)
Parity
0 48 (45%) 53 (49%) 101 (47%)
1 37 (35%) 36 (33%) 73 (34%)
≥ 2 22 (20%) 20 (18%) 42 (19%)
Number of previous stillbirths
1 1 (1%) 1 (1%) 2 (1%)
Obstetric history for previous pregnancies1
Yes 23 (21%) 19 (17%) 42 (19%)
Obstetric cholestasis 0 (–) 4 (4%) 4 (2%)
Placental abruption 2 (2%) 1 (1%) 3 (1%)
Preeclampsia 5 (5%) 1 (1%) 6 (3%)
SGA baby 5 (5%) 2 (2%) 7 (3%)
Other 16 (15%) 14 (13%) 30 (14%)
Diagnoses in current pregnancy1
Antepartum haemorrhage 0 (–) 1 (1%) 1 (< 1%)
Hypertension 1 (1%) 1 (1%) 2 (1%)
Obstetric cholestasis 0 (0%) 2 (2%) 2 (1%)
Other2 6 (6%) 4 (4%) 10 (5%)
Past medical history1 15 (14%) 12 (11%) 27 (13%)
Hypertension 4 (4%) 0 (–) 4 (2%)
Diabetes 2 (2%) 0 (–) 2 (1%)
Other3 10 (9%) 12 (11%) 22 (10%)
Estimated fetal weight from ultrasound scan (g)
Mean (SD) 3255 (520.6) 3109 (500.1) 3181 (514.4)
Centile using INTERGROWTH-21st birthweight standard
Mean (SD) 67.4 (24.7) 59.1 (25.8) 63.3 (25.6)
SGA fetus 3 (3%) 5 (5%) 8 (4%)
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Table 1 Baseline characteristics (Continued)
Characteristic Control (n = 107) Intervention (n = 109) Total (n = 216)
Prescribed medication at the trial entry1
Aspirin 8 (7%) 7 (6%) 15 (7%)
Other4 10 (9%) 11 (10%) 21 (10%)
Substance misuse during this pregnancy
Benzodiazepine 0 (–) 3 (3%) 3 (1%)
Cigarette smoking status during this pregnancy
Currently smoking 5 (5%) 3 (3%) 8 (4%)
Stopped smoking in this pregnancy 5 (5%) 4 (4%) 9 (4%)
Not smoked in this pregnancy 97 (91%) 102 (94%) 199 (92%)
Duration women concerned about baby’s movements (h)
0–24 76 (71%) 72 (66%) 148 (69%)
25–48 9 (8%) 18 (17%) 27 (13%)
> 48 22 (21%) 19 (17%) 41 (19%)
Absent fetal movements
Yes 37 (35%) 51 (47%) 88 (41%)
No 70 (65%) 58 (53%) 128 (59%)
All data are N (%) unless indicated
1Categories are not mutually exclusive
2Others include anxiety and depression (n = 2), gestational diabetes, placenta praevia, medullary sponge kidney, hypothyroidism, gallstones/pancreatitis, type 1
diabetes, GBS, thrush and fibromyalgia (not mutually exclusive)
3Others include significant cardiac disease (n = 3), significant gastrointestinal problems (n = 3), significant mental health problems (n = 10), renal disease (n = 1)
and thyroid disease (n = 7)
4Others include antidepressants (n = 14), benzodiazepines (n = 3) and low molecular weight heparin (n = 6)
Table 2 Compliance with allocated trial intervention
Control (n = 107) Intervention (n = 109)
Trial blood sample taken 107 (100%) 109 (100%)
Blood sample analysed at site
Yes 0 (–) 109 (100%)
No 107 (100%) 0 (–)
sFlt-1/PlGF ratio obtained by site and revealed to participant – 109 (100%)
Test result (sFlt-1/PlGF ratio) –
Mean (SD) – 21.1 (23.9)
Median (25th, 75th centile) – 14.8 (5.3, 27.8)
Min, max – 0.6, 151.1
Expedited delivery offered sFlt-1/PlGF ratio < 38 (n = 93) sFlt-1/PlGF ratio ≥ 38 (n = 16)
Yes 9 (8%) 81 (9%) 15 (94%)
No 98 (92%) 85 (91%) 12 (6%)
Expedited delivery accepted
Yes 9 (100%) 8 (100%) 12 (80%)
No 0 (–) 0 (–) 33 (20%)
All data are N (%) unless indicated
1Reasons for offering expedited delivery in the intervention arm with sFlt-1/PlGF ratio < 38 include the following: participant wanted induction of labour even
though not indicated (n = 2), clinician decision to deliver baby (n = 5) and participant offered induction for recurrent RFM (n = 1)
2Reasons for not offering expedited delivery in the intervention arm with sFlt-1/PlGF ≥ 38 include the following: clinician decision to continue pregnancy (n = 1)
3Reasons for not accepting expedited delivery in the intervention arm with sFlt-1/PlGF ≥ 38 include the following: would like delivery on midwife-led unit, feels
well and baby at the time was moving well (n = 1); discussed results with husband and decided not to accept expedited delivery (n = 1); induction date booked
in 1 weeks’ time, would like to stay with that plan (n = 1)
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these were in the intervention arm (12 in the intervention
arm versus 4 in the control arm).
The median length of stay in the hospital for babies
was 1.2 days (interquartile range 0.7 to 2.2). Overall, 12
babies were admitted to the neonatal unit (7 in the inter-
vention arm, 5 in the control arm), none of whom re-
quired therapeutic cooling (Table 5). The number of
dependency days on the neonatal unit varied with the
level of care being received (Table 5). Of the 7 babies in
the intervention arm admitted to the neonatal unit, 1
had a length of stay < 24 h, 2 were admitted for 1–2 days
and 4 were on the neonatal unit for > 2 days. Of the 5
babies in the control arm admitted to the neonatal unit, 1
had a length of stay of 1–2 days and 4 were admitted for
> 2 days. Mechanical respiratory support was provided for
5 babies (3 in the intervention arm, 2 in the control arm);
2 babies in the intervention arm required this respiratory
support for < 24 h, while 1 baby in the intervention arm
and 2 in the control arm needed respiratory support for
1–2 days (Table 5).
Central lab analysis and diagnostic performance of sFlt-1
and PlGF
A comparison of sFlt-1/PlGF ratio results for interven-
tion arm samples tested at both the sites and the central
lab showed good agreement (central lab versus site,
mean difference 0.46, SD 4.04; Additional file 3). Of the
93 samples with a sFlt-1/PlGF ratio < 38 tested at the
sites, 92 were also < 38 in central lab testing. A total of
16 samples tested at sites had a sFlt-1/PlGF ratio ≥ 38,
while the central lab reported 17 samples with this result
which gave an unweighted kappa of 0.96.
For the 107 participants in the control arm, central lab
analysis showed 88 (82%) had a sFlt-1/PlGF ratio result
< 38, while 18 (17%) had a sFlt-1/PlGF ratio result ≥ 38.
The blood sample for 1 participant was erroneously
destroyed and could not be tested. Of the 88 participants
with a sFlt-1/PlGF ratio < 38, 3 (3%) had the composite
adverse pregnancy outcome, while 1/18 (6%) with a sFlt-
1/PlGF ratio ≥ 38 had the composite which gave an area
under the ROC (AUROC) curve of 0.48 (95% CI 0.16 to
0.79; Fig. 2) as a measure of the diagnostic performance
in the control arm.
Discussion
This randomised controlled pilot trial has provided im-
portant information which will help guide the design
and conduct of a larger main trial in women with RFM.
Sufficient numbers of eligible women were available and
we were able to recruit to target. The length of time in-
dividual sites were open to recruitment varied with half
the sites being open for only 5–6 months (Additional file
2) which is extremely encouraging for a main trial and
suggests that recruitment could have been above target
with a faster site set-up time.
The percentage of eligible women randomised varied
across sites (41–83%; Additional file 2) from those who
were approached. Resource or staff issues and potentially
eligible women being missed were the main reasons for
not approaching women and are limitations of this pilot
trial. Due consideration would need to be given to strat-
egies to overcome this in a future trial, potentially in-
cluding the provision of out-of-hours resource to ensure
that women presenting at any time of the day can be
approached. Additional methods for raising awareness of
the trial would also need to be developed as a reminder
for trial staff.
Table 3 Completeness of data collection for planned outcomes in a main trial
Outcome Control (n = 107) Intervention (n = 109) Total (n = 216)
Completeness of each component of proposed primary outcome
Stillbirth or death before discharge 107 (100%) 109 (100%) 216 (100%)
5-min Apgar score 107 (100%) 109 (100%) 216 (100%)
Umbilical artery pH 62 (58%) 72 (66%) 134 (62%)
Length of stay in neonatal unit 107 (100%) 109 (100%) 216 (100%)
Number of primary outcome components with complete
data for each participant
0 0 (–) 0 (–) 0 (–)
1 0 (–) 0 (–) 0 (–)
2 0 (–) 0 (–) 0 (–)
3 45 (42%) 37 (34%) 82 (38%)
4 62 (58%) 72 (66%) 134 (62%)
Participants with assessable composite primary outcome1 107 (100%) 109 (100%) 216 (100%)
1Primary outcome is assessable if all components are complete, or if any component is positive regardless of missing data, or if umbilical artery pH is missing and
all other components are negative
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The baseline characteristics of participants in both
allocated trial arms were comparable to previous cohort
and intervention studies of RFM [16, 18]. Compliance
with the trial interventions was excellent for the blood
testing process and adherence to the offer of expedited
delivery for those in the intervention arm with a sFlt-1/
Table 4 Maternal proof of concept outcomes
Control (n = 107) Intervention (n = 109)
Complications of pregnancy after baseline visit1 5 (5%) 15 (14%)
Antepartum haemorrhage 2 (2%) 2 (2%)
Hypertension in pregnancy 2 (2%) 3 (3%)
Obstetric cholestasis 2 (2%) 1 (1%)
Prelabour rupture of membranes 1 (1%) 9 (8%)
Other2 1 (1%) 3 (3%)
Onset of labour
Spontaneous 49 (46%) 50 (46%)
Induced 48 (45%) 49 (45%)
Caesarean section 10 (9%) 10 (9%)
If caesarean section, grade
Grade 1 (emergency) 2 (20%) 1 (10%)
Grade 4 (elective) 8 (80%) 9 (90%)
Reasons for induction3
Recommended by sFlt-1/PlGF test result 0 (–) 13 (27%)
Gestational age > 41 weeks 8 (17%) 7 (14%)
Term (> 37 weeks) prelabour rupture of membranes > 24 h 3 (6%) 5 (10%)
Fetal growth restriction 2 (4%) 1 (2%)
Reduced fetal movements 29 (60%) 25 (51%)
Pregnancy-induced hypertension 0 (–) 1 (2%)
Preeclampsia 1 (2%) 0 (–)
Obstetric cholestasis 1 (2%) 2 (4%)
Gestational diabetes 1 (2%) 2 (4%)
Maternal request 2 (4%) 3 (6%)
Other 14 (29%) 5 (10%)
Reasons for elective caesarean4
Recommended by sFlt-1/PlGF test result 0 (–) 1 (11%)
Previous caesarean section 4 (50%) 5 (56%)
Non-cephalic presentation 2 (25%) 3 (33%)
Presumed fetal compromise 1 (13%) 0 (–)
Maternal request 0 (–) 2 (22%)
Previous 3rd/4th degree tear 0 (–) 1 (11%)
Other 2 (25%) 3 (33%)
Mode of delivery
Vaginal birth 72 (67%) 64 (59%)
Instrumental vaginal birth 14 (13%) 25 (23%)
Emergency caesarean section 13 (12%) 11 (10%)
Elective caesarean section 8 (7%) 9 (8%)
1Complications of pregnancy are not mutually exclusive
2Others include spontaneous rupture of membranes, viral meningitis, polyhydramnios and genital ulcer (microbiology confirmed HSV-1)
3Reasons for induction are not mutually exclusive; denominator is the number of participants who were induced
4Reasons for elective caesarean are not mutually exclusive; denominator is the number of participants who had an elective caesarean section
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PlGF ratio ≥ 38. A small number of participants in both
the intervention arm with a sFlt-1/PlGF ratio < 38 and
the control arm were also offered expedited delivery
which was to be expected as part of standard care and
may reflect other pregnancy complications which oc-
curred after recruitment into the trial such as prelabour
rupture of membranes or gestational hypertension.
Completeness of data collection was also excellent for
the vast majority of the proposed primary and secondary
outcome measures for a main trial. One of the limitations
of this trial was collection of umbilical artery pH data,
however, this is often not measured in babies who are
otherwise healthy at birth, particularly as higher Apgar
scores at 5min are associated with less acidic umbilical ar-
tery pH values [32, 33]. Thus, any babies where this data
was missing were assumed to have had an umbilical artery
pH ≥ 7.05, especially as they all had a 5-min Apgar score ≥
7. For a main trial, further consideration would need to be
given to the use of appropriate and clinically important
outcome measures that are routinely collected to ensure
Table 5 Neonatal proof of concept outcomes
Control (n = 107) Intervention (n = 109)
Composite adverse pregnancy outcome1 4 (4%) 9 (8%)
Stillbirth or death before discharge 0 (–) 0 (–)
5-min Apgar score < 7 1 (1%) 1 (1%)
Umbilical artery pH < 7.05 0 (–) 4 (4%)
Admission to neonatal unit for > 48 h 4 (4%) 4 (4%)
Other neonatal outcomes
SGA baby (INTERGROWTH-21st birthweight standard) 2 (2%) 9 (8%)
SGA baby (GROW birthweight standard) 7 (7%) 15 (14%)
Length of stay in hospital (days)
Median (25th, 75th centile) 1.2 (0.8, 2.2) 1.2 (0.7, 2.4)
Outcomes for babies admitted to neonatal unit n = 5 n = 7
Use of therapeutic cooling 0 (-) 0 (–)
Duration of mechanical respiratory support
< 24 h 0 (–) 2 (29%)
1–2 days 2 (40%) 1 (14%)
Length of stay in neonatal unit2
Normal care n = 0 n = 1
< 24 h 0 (–) 0 (–)
1–2 days 0 (–) 1 (14%)
> 2 days 0 (–) 0 (–)
Special care n = 5 n = 6
<24 h 0 (–) 1 (14%)
1–2 days 2 (40%) 2 (29%)
> 2 days 3 (60%) 3 (43%)
High dependency care n = 5 n = 2
< 24 h 0 (–) 1 (14%)
1–2 days 1 (20%) 1 (14%)
> 2 days 2 (40%) 0 (–)
Intensive care n = 1 n = 1
< 24 h 0 (–) 1 (14%)
1–2 days 1 (20%) 0 (–)
> 2 days 0 (–) 0 (–)
All data are N (%) unless indicated
1This means at least one of stillbirth or death before discharge, 5-min Apgar score of < 7, umbilical artery pH < 7.05, or admission to the neonatal unit for > 48 h. If
umbilical artery pH was missing (n = 82) and all other components did not indicate the composite adverse pregnancy outcome, an umbilical artery pH ≥ 7.05 was
assumed for the purposes of calculating the composite
2Levels of care are not mutually exclusive
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the results are robust and widely generalisable. Another
limitation of the trial was the response rate for the Postna-
tal Questionnaire (131/216; 61%; Fig. 1) and in a main
trial, options for increasing this could be included such as
providing the opportunity to complete questionnaires on-
line or text alerts sent before and after the questionnaire.
These results have built on the initial findings from
the ReMIT trial [16] and further demonstrate that a
main trial to assess placental function via a biomarker in
maternal blood in combination with delivery, as indi-
cated by the biomarker, is feasible in women with RFM.
There was no difference in IOL and planned caesarean
section rates between the two allocated trial arms, and the
frequency of IOL for RFM was very similar. Interestingly,
the proportion of IOL recommended by the sFlt-1/PlGF
ratio was comparable with the proportion having IOL
based on the hPL result in the ReMIT trial (27% versus
30% [16];) although the numbers are too small to draw
any conclusions and it is plausible that a similar propor-
tion of cases had evidence of placental dysfunction.
Although a higher proportion of babies in the interven-
tion arm had the composite adverse pregnancy outcome
compared with the control arm (difference was due to 4
babies in the intervention arm having an umbilical artery
pH > 7.05), the numbers are too small to draw any firm
conclusions. Overall, the composite adverse pregnancy
outcome occurred in 13/216 (6%) babies. In the first Re-
MIT trial, the comparable composite poor pregnancy out-
come of stillbirth, admission to NICU or umbilical artery
pH < 7.1 occurred in 8/120 (7%) babies; this increased to
24/120 (20%) babies when birthweight ≤ 10th centile was
included in the composite [16]. Interestingly, of the SGA
babies in ReMIT-2, a slightly greater proportion were de-
livered prior to 39 weeks’ gestation in the intervention arm
than in the control arm suggesting that identification of
SGA babies in the intervention arm was more likely, which
then prompted delivery. This observation would be con-
sistent with the findings of the review of diagnostic test ac-
curacy studies [17]. Nevertheless, the use of a composite
outcome is a limitation of the current trial and our find-
ings reinforce the need to ensure appropriate outcome
measures are used in a main trial to enable robust conclu-
sions to be drawn. Consideration will be given to inclusion
of birthweight ≤ 10 centile in the composite adverse preg-
nancy outcome for a main trial, particularly in light of the
updated NHS Saving Babies’ Lives Care Bundle released in
2019 which includes management of babies at risk of fetal
growth restriction as one of its key standards [3] and evi-
dence that identification of a SGA fetus at term prior to
labour is associated with improved outcome at birth [34].
Diagnostic performance of the sFlt-1/PlGF ratio in the
control arm gave an AUROC of 0.48 (95% CI 0.16 to 0.79)
however, as the number of participants with a composite
adverse pregnancy outcome was so small, caution is
advised in any interpretation of this result as the 95% CI is
very wide. Encouragingly, of the 215 participants with a
sFlt-1/PlGF ratio result, 34 (15.8%) were ≥ 38, which was
similar to the proportion seen in the pre-trial diagnostic
test accuracy work (12.8%) suggesting that the test is per-
forming consistently in women with RFM [23].
Although most research utilising the sFlt-1/PlGF ratio in
placental dysfunction has been targeted at preeclampsia
[21], more recent work has been investigating the use of
these biomarkers for detecting other pregnancy complica-
tions such as the identification of SGA babies [35–37],
fetal compromise associated with RFM [18] and gestational
hypertension and placental abruption [38]. It is likely that
interest will increase in the use of biomarkers combined
Fig. 2 Receiver operator characteristic curve for sFlt-1/PlGF ratio and composite adverse pregnancy outcome in the control arm
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with other aspects of care for the management of RFM
after results from the AFFIRM trial indicated that a care
package for RFM did not significantly reduce the rate of
stillbirth but increased the rate of obstetric intervention
[39]. Further work to investigate the potential of placental
biomarkers to aid prediction of adverse pregnancy out-
comes in areas such as RFM is therefore warranted.
Conclusions
We have demonstrated that a large main trial assessing
placental dysfunction via a biomarker in combination
with delivery, as indicated by the biomarker, in women
with RFM ≥ 36 weeks’ gestation is feasible based on
meeting the recruitment target and excellent compliance
with the trial interventions. Some aspects of the design
require modification, in particular further consideration
will be given to selecting the most accurate biomarker and
the most appropriate and clinically important outcome
measures to ensure robust conclusions can be drawn.
Results from an adequately powered main trial would help
address key areas for action noted in the two perinatal
Confidential Enquiries [11, 12] and some of the Stillbirth
Priority Setting Partnership research priorities, notably
“Can the wider use of existing tests and monitoring proce-
dures, especially in later pregnancy, and the development
and implementation of novel tests (biomarkers) in the
mother or in early pregnancy, help prevent stillbirth?” [13].
In addition, it would provide further evidence to guide the
management of RFM with the ultimate aim of reducing the
rate of stillbirth in line with national ambition while redu-
cing unnecessary obstetric intervention [3].
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